Open AccessCemiplimab (Libtayo)
Author(s) -
CADTH
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.365
Subject(s) - anaplastic lymphoma kinase , medicine , oncology , pembrolizumab , lung cancer , epidermal growth factor receptor , ros1 , crizotinib , nivolumab , cancer , immunotherapy , adenocarcinoma , malignant pleural effusion